Milestone Pharmaceuticals to Report Q3 Results
The cardiovascular drugmaker will release third quarter 2026 financial results and host an investor call on November 13, 2026.
Updated on Nov. 3, 2026 in Corporate Finance
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) will report its third quarter 2026 financial results, covering the period ended September 30, 2026, on November 13, 2026. The company will host a conference call and webcast for investors at 8:30 am ET that day.
Why it matters
The quarterly report and investor call give shareholders and analysts a scheduled opportunity to review the company's financial position and business update. Milestone is a biopharmaceutical company focused on cardiovascular medicines, and its commercial product CARDAMYST (etripamil) nasal spray is FDA-approved for conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhythm in adults.
The release is a scheduled disclosure, so the reported financial figures are not yet known. The company's results will be released November 13, 2026, and their content has not been disclosed.
The players
Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals is a biopharmaceutical company trading on Nasdaq under the symbol MIST, focused on developing cardiovascular medicines.
The details
Milestone Pharmaceuticals announced the date of its third quarter 2026 earnings release and investor call. Participants can register for the live conference call through a registration link or use guest dial-in numbers, and a replay of the audio webcast will be posted on the company's website under the News & Events section.
Timeline
September 30, 2026: Third quarter 2026 reporting period ends.
November 3, 2026: Earnings announcement date notice issued.
November 13, 2026, 8:30 am ET: Third quarter results reported and investor conference call held.
Corporate Finance Context
Quarterly earnings releases for commercial-stage biopharmaceutical companies like Milestone are the primary scheduled channel through which investors track progress on FDA-approved products. The CARDAMYST nasal spray, approved for paroxysmal supraventricular tachycardia, anchors the company's current revenue narrative.
Shareholders and prospective investors can join the November 13 call by registering through the company's link or dialing in with the listed numbers, with the Call Me option available for instant access. A replay of the audio webcast will be available on Milestone's website for those who cannot attend live.
The takeaway
Investors who want to follow Milestone's progress should note the November 13 call time and plan to listen live or access the replay. Reviewing the reported figures alongside the company's stated product updates will give the clearest read on performance.
What happens next
Milestone Pharmaceuticals will report third quarter 2026 financial results and host its investor conference call on November 13, 2026, at 8:30 am ET.
Further reading
For more on how companies report and investors respond, explore Corporate Finance.
More information
The audio replay of the call will be posted in the News & Events section of the Milestone Pharmaceuticals website.
Source note: This article includes information reported by The Manila times.
